cevostamab

An investigational, humanized IgG-based T-cell–engaging bispecific antibody

A T-cell–engaging bispecific antibody, cevostamab is designed to bind to FcRH5, a B-cell lineage marker expressed with near 100% prevalence on myeloma cells, and to CD3 on T cells¹

CD=cluster of differentiation; FcRH5=Fc receptor homolog 5; IgG=immunoglobulin G.